This is an early-stage pipeline update with no financial or regulatory catalyst. Monitor for IND filing later in 2026 and subsequent clinical data. The preclinical selectivity profile is promising but has not yet been validated in human trials.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 12 $33.10entry
- T+1 · 5mo ago +0.21%α −1.55% · $33.17
- T+5 · 5mo ago +4.35%α +3.68% · $34.54
- T+20 · 4mo ago +17.43%α +15.65% · $38.87
- T+60 · 2mo ago +6.59%α +3.32% · $35.28
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cogent Biosciences presented preclinical data for its novel JAK2 V617F mutant-selective inhibitor CGT1145 at the EHA Congress, highlighting >100x selectivity over JAK2 WT and JAK1/3 isoforms. The program remains on track for an IND submission in 2026. The data is early-stage and does not involve financial results or regulatory decisions, limiting near-term stock impact.
Key Facts
- CGT1145 is a potent, selective inhibitor of JAK2 V617F with >100x selectivity over JAK2 WT and JAK1/3 isoforms
- Preclinical data presented at the 2026 EHA Congress in Stockholm
- IND submission planned for 2026
- JAK2 V617F is the most prevalent mutation in BCR-ABL-negative MPNs, occurring in ~95% of polycythemia vera patients and ~50% of primary myelofibrosis / essential thrombocythemia patients
Financial Impact
No financial data provided; preclinical program with no revenue impact at this stage
Risk Factors
- Preclinical data may not translate to clinical efficacy or safety in humans
- Competitive landscape includes approved JAK inhibitors with established profiles
- IND filing timeline could face delays
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311017 |
Track record
13 reports on COGT
5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +17.43% at T+20 after the Jun 12, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $33.54 Now $27.44 −18.19% settles Feb 5
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $31.65 Now $27.44 −13.29% settles Feb 4
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 5/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
- Aug 9, 202614w ago Institutional Cluster Bullish 6/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
- Jun 12, 202622w ago Press Release Neutral 4/10 Viewing Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
- Jun 12, 202622w ago Press Release Bullish 7/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
- May 30, 202624w ago Press Release Bullish 8/10 Entry $34.81 to $36.80 Now $27.44 −21.17% ▲ +5.72% +4.49% vs SPY
- May 28, 202624w ago Press Release Bullish 8/10 Entry $35.38 to $36.73 Now $27.44 −22.44% ▲ +3.82% +2.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers